BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
Open Access
- 22 January 2009
- journal article
- editorial
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 16 (4) , 801-803
- https://doi.org/10.1245/s10434-008-0298-z
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Presence of BRAF V600E in Very Early Stages of Papillary Thyroid CarcinomaThyroid®, 2007
- Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): A mono‐institutional experienceJournal of Surgical Oncology, 2007
- Lymph node metastases in differentiated thyroid cancer under 2 cmSurgery, 2006
- Managing Small Thyroid CancersJAMA, 2006
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006
- BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid CancerJournal of Clinical Endocrinology & Metabolism, 2005
- The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma.International Journal of Oncology, 2004
- Increased Incidence of Thyroid Carcinoma in France: A True Epidemic or Thyroid Nodule Management Effects? Report from the French Thyroid Cancer CommitteeThyroid®, 2004
- Papillary microcarcinoma of the thyroid—Prognostic significance of lymph node metastasis and multifocalityCancer, 2003
- Symptomatic versus Asymptomatic Papillary Thyroid Microcarcinoma: A Retrospective Analysis of Surgical Outcome and Prognostic Factors.Endocrine Journal, 1999